In a research note released today, Roth Capital reiterated coverage on TG Therapeutics, Inc. (TGTX) with a Buy rating and a price target of $15.
In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …
In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Palatin Technologies, Inc. (PTN) and a price target of $6.
In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …
In a research note issued today, Roth Capital reiterated coverage with a “Sell” rating on Dendreon Corporation (DNDN) and lowered its price target to $0.50 from …
